About
TRiCBIO provides human organoid-based research services for drug discovery, efficacy, safety, mechanism, immune-context, and custom model development. It works with biopharma, CRO, and research collaboration projects, with studies run from Nanjing and project support from Shanghai and Philadelphia.
Services
Organoid target discovery & functional genomics
Discover genetic dependencies through organoid library screening and validate targets with tumor, microenvironment, and treatment-response readouts.
Target validation & mechanism studies
Test candidate targets in human organoids through disease phenotypes, molecular changes, and treatment response.
Mechanism & biomarker studies
Link tissue, functional, and molecular results to treatment response and prioritize biomarker candidates for validation.
Custom model development
Develop model and assay plans for specialized tissues, rare diseases, or complex co-cultures based on available samples and endpoints.
Organoid efficacy screening
Compare single agents and combinations in tumor PDOs and selected human organoid models to identify dose responses and differences across models.
Immuno-oncology
Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures with tissue imaging and functional assays.
Antibody, multispecific & T-cell engager (TCE) studies
Compare tumor-cell killing, immune activation, and cytokine changes for antibody, multispecific, and TCE candidates in human tumor organoids and immune co-cultures.
ADC research
Combine target expression, spatial distribution, cytotoxicity, and bystander-effect readouts in organoid studies matched to ADC candidates.
Safety & toxicology
Compare dose- and exposure-related responses in normal-tissue organoids using morphology, function, and injury markers to assess organ risk.
Multi-organ safety in human organoids
Compare normal kidney, lung, and GI organoids with adjacent non-tumor liver or other models in coordinated exposure designs to rank organ risks.
Drug delivery & barrier permeability
Assess barrier integrity, injury, and repair, then develop permeability or candidate-transport assays for the relevant tissue system.
Mechanism & biomarkers
Link tissue, functional, and molecular results to treatment response and prioritize biomarker candidates for validation.
Human intestinal organoid IBD-like inflammation model
Study IBD-like inflammation in human intestinal organoids through morphology, FITC-Dextran, IL-8, and image-based candidate readouts.
Tailored ADPKD organoid cyst-phenotype studies
Develop cyst-phenotype and candidate-intervention studies for autosomal dominant polycystic kidney disease using hPSC-derived kidney organoids.
BBB co-culture & permeability methods
Build HUVEC–astrocyte co-culture and ZO-1 junction imaging methods with permeability, candidate-response, and transport assays.
- What to send
- Tell us your study objective, candidate or sample, and the result that matters most. · Share the study objective and any available sample or candidate context.
Capabilities
- Assays and studies
- Antibodies · ADCs · Flow cytometry · Toxicology · Small molecules · Library screening · Functional genomics · Target validation · Mechanism studies · Morphology · Histology · Immunofluorescence
12 more
Cytokine assays · Viability · Apoptosis · Gene expression/qPCR · Barrier permeability · Transport assays · Injury marker analysis · Genetic-library screening · Treatment-response studies · Functional assays · H&E · IHC - Scale and capacity
- ALI · 96-well adaptable · 24-well · 96-well adaptable
- Therapeutic areas
- Oncology · Immuno-oncology · Kidney injury · Gastrointestinal disease · Inflammatory bowel disease · ADPKD · Blood-brain barrier · Head and neck cancer · Mesenchymal tumors · Drug discovery · Drug development · Safety
3 more
Inflammation · Inherited kidney disease · Neurovascular-barrier research
Instruments and platforms
- Flow cytometry
- H&E
- IHC
- IF
- Microscopy equipment
Modalities and species
- Modalities
- Small molecule · Antibody · Bispecific · ADC
- Species and models
- Human tumor organoids · Human kidney organoids · Normal lung organoids · Human intestinal organoids · Adjacent non-tumor liver organoids · H9 human embryonic stem cell (hESC)-derived kidney organoids · HUVEC–astrocyte co-culture · Patient-derived tumor organoids (PDO 1.0, PDO 2.0 / ALI) · IBD-like intestinal organoid model · ADPKD hPSC-derived kidney organoids · Human organoids · PDO 1.0
6 more
PDO 2.0 · ALI tumor-immune organoids · Tumor PDOs · Normal-tissue organoids · Human intestinal organoid · hPSC-derived kidney organoids
Industries served
- Biopharma
- CRO
- Biotech
- Academic research
Company
- Type
- CRDMO
- Quality
- Model QC (morphology, markers and functional readouts) · batch QC (model and assay summary, model/batch QC, original images or data, and study report) · model quality assessed through morpholog · methods, results and data sources docume
Locations
- Based in
- Nanjing, China
- Sites
- Nanjing, China · Shanghai, China · Philadelphia, US
- Serves
- China, global, global clients
Contacts
- Phone
- +86 400 880 3160
Similar labs
Work here? Claim this listing